KCS
MCID: KRT001
MIFTS: 59

Keratoconjunctivitis Sicca (KCS) malady

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

Aliases & Descriptions for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 50 29 52 42 14 69
Keratitis Sicca 50 69
Xerophthalmia 50 69
Dry Eye Syndromes 69
Dry Eye Syndrome 50
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 42 D007638
UMLS 69 C0022575

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to cataract and keratoconus, and has symptoms including dryness of eye, eye manifestations and dacryops. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Cyclosporine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and liver, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 71 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
id Related Disease Score Top Affiliating Genes
1 cataract 29.8 ALB IL1B TNF
2 keratoconus 29.6 IL1B IL6 TNF
3 rheumatoid arthritis 29.3 CD79A IL1A IL1B IL4 IL6 TLR4
4 xerophthalmia 12.3
5 sjogren's syndrome 11.6
6 myelopathy, htlv-1-associated 11.1
7 retrovirus-associated myelopathy 11.1
8 tropical spastic paraparesis 11.1
9 dry eye syndrome 11.1
10 keratoconjunctivitis 11.0
11 atopic dermatitis 6 10.3 ALB CD79A
12 polyneuropathy due to drug 10.3 CD79A IL1A IL4
13 infertility due to extratesticular cause 10.3 ALB CD79A LTF
14 ciliary discoordination, due to random ciliary orientation 10.3 ALB CD79A IL1A
15 congenital dyserythropoietic anemia 10.3 ALB TNF
16 colloid adenoma 10.3 ALB CD79A
17 tubular renal disease-cardiomyopathy syndrome 10.3 IL4 TNF
18 schneiderian carcinoma 10.2 ALB CD79A
19 lymphangiectasia, intestinal 10.2 CD79A IL4 NGF
20 malignant renovascular hypertension 10.2 CD79A NGF
21 hypotrichosis 4 10.2 IL1A IL4 TNF
22 osteodysplasty precocious of danks mayne and kozlowski 10.2 CD79A IL4 TNF
23 spastic entropion 10.2 ALB CD79A IL1A LTF
24 oral cavity cancer 10.2 CD79A IL4 TNF
25 autonomic peripheral neuropathy 10.2 ALB CD79A TLR9
26 dermatomycosis 10.2 ALB CD79A TNF
27 patellar tendinitis 10.2 ALB IL4 TLR9
28 toxic optic neuropathy 10.2 CD79A IL1A IL1B
29 intussusception 10.2 IL1B TNF
30 acquired polycythemia 10.2 CD79A IL4 TNF
31 xanthogranulomatous cholecystitis 10.2 CD79A IL4 TNF
32 choreatic disease 10.2 ALB CD79A TNF
33 uterine ligament serous adenocarcinoma 10.2 ALB CD79A NGF
34 arthritis 10.2
35 childhood choriocarcinoma of the testis 10.2 CD79A IL1A IL4 TLR9
36 psychotic disorder 10.2 IL4 IL6 LTF
37 retinal vascular disease 10.2 IL4 IL6 LTF
38 acute dacryoadenitis 10.1 ERBB2 IL4 TNF
39 newcastle disease 10.1 CD79A TLR9 TNF
40 immune-complex glomerulonephritis 10.1 CD79A IL4 IL6
41 uterus interstitial leiomyoma 10.1 ALB CD79A IL4 TNF
42 epidermolysis bullosa 10.1 CD79A IL1A IL4 TNF
43 cerebellar disease 10.1 IL1A IL1B TNF
44 tracheitis 10.1 CD79A IL4 NGF TNF
45 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.1 IL6 TNF
46 familial renal papillary carcinoma 10.1 ALB CD79A TNF
47 paragonimiasis 10.1 ALB IL6 LTF
48 tularemia 10.1 CD79A IL4 TLR9 TNF
49 wound botulism 10.1 CD79A IL1B TNF
50 motor peripheral neuropathy 10.1 CD79A IL4 TLR9 TNF

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


dryness of eye, eye manifestations, dacryops

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 TLR4 TLR9 TNF VSIG4 ALB CD79A
2 immune system MP:0005387 10.3 CD79A CLEC4F ERBB3 HSPG2 IL1A IL1B
3 hematopoietic system MP:0005397 10.27 CD79A CLEC4F HSPG2 IL1A IL1B IL4
4 cellular MP:0005384 10.26 ALB CD79A ERBB2 ERBB3 HSPG2 IL4
5 cardiovascular system MP:0005385 10.24 ERBB2 ERBB3 HSPG2 IL1A IL1B IL6
6 digestive/alimentary MP:0005381 10.21 ALB ERBB2 ERBB3 HSPG2 IL4 IL6
7 mortality/aging MP:0010768 10.15 ALB ERBB2 ERBB3 HSPG2 IL1B IL4
8 integument MP:0010771 10.13 ERBB2 ERBB3 HSPG2 IL1A IL1B IL4
9 liver/biliary system MP:0005370 10.01 ALB CD79A HSPG2 IL4 IL6 LTF
10 muscle MP:0005369 9.97 TNF ALB ERBB2 ERBB3 HSPG2 IL6
11 neoplasm MP:0002006 9.96 IL6 LTF TLR4 TNF ALB CD79A
12 nervous system MP:0003631 9.9 TNF CD79A ERBB2 ERBB3 HSPG2 IL1B
13 normal MP:0002873 9.56 ALB CD79A ERBB2 ERBB3 IL4 LTF
14 respiratory system MP:0005388 9.17 IL6 TLR4 TNF ERBB2 ERBB3 HSPG2

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
4
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 299-42-3 9294
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90-82-4 7028
6
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
9
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
10
Calcium carbonate Approved Phase 4 471-34-1
11
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
14
Glycerol Approved, Experimental Phase 4,Phase 2,Phase 3 56-81-5 753
15
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
16
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
17
Ethanol Approved Phase 4,Phase 2 64-17-5 702
18
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
19
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
20
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
23
Ofloxacin Approved Phase 4 82419-36-1 4583
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
25
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
26
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
27
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
28
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
29
Travoprost Approved Phase 4 157283-68-6 5282226
30
Pilocarpine Approved Phase 4 54-71-7, 92-13-7 5910
31
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
32
Sulfacetamide Approved Phase 4 144-80-9 5320
33
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
34
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
35
Tobramycin Approved, Investigational Phase 4,Phase 1 32986-56-4 5496 36294
36
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
37
Lymecycline Approved Phase 4 992-21-2 5280963
38
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
41
Dehydroepiandrosterone Approved, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
42
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
43 tannic acid Approved, Nutraceutical Phase 4
44
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
45
Maleic acid Experimental Phase 4 110-16-7 444266
46 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
50 Carboxymethylcellulose Sodium Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 681)
id Name Status NCT ID Phase
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
2 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4
3 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4
4 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
5 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4
6 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4
7 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4
8 Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance Unknown status NCT01589640 Phase 4
9 Lipids of the Human Tear Film and Their Effect on Tear Stability Unknown status NCT00803452 Phase 4
10 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4
11 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4
12 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
13 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4
14 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4
15 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4
16 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
17 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
18 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4
19 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
20 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4
21 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4
22 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
23 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4
24 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4
25 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4
26 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
27 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4
28 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4
29 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
30 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4
31 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4
32 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4
33 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4
34 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
35 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4
36 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4
37 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4
38 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
39 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4
40 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4
41 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
42 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4
43 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4
44 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4
45 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4
46 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4
47 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
48 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
49 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4
50 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

id Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 29

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

39
Eye, Testes, Liver, T Cells, Salivary Gland, Bone, Bone Marrow

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 341)
id Title Authors Year
1
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
2
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
3
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2016
4
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
5
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
6
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
7
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
8
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
9
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
10
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
11
Erratum to: Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27919262 )
2016
12
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2016
13
Assessment of tear film osmolarity using the TearLab(a8c) osmometer in normal dogs and dogs with keratoconjunctivitis sicca. ( 27761982 )
2016
14
Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. ( 25747049 )
2015
15
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. ( 25664315 )
2015
16
Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. ( 26466228 )
2015
17
Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. ( 25675975 )
2015
18
Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. ( 25802852 )
2015
19
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. ( 26628876 )
2015
20
Salivary gland scintigraphy in patients suffering from severe keratoconjunctivitis sicca. Evaluation of the viability of submandibular glands before and after transfer into the temporal fossa. ( 26083667 )
2015
21
Retrospective study of the prevalence of keratoconjunctivitis sicca in diabetic and nondiabetic dogs after phacoemulsification. ( 25429857 )
2014
22
Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca. ( 24395332 )
2014
23
Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology. ( 25378890 )
2014
24
Uveodermatologic syndrome concurrent with keratoconjunctivitis sicca in a miniature poodle dog. ( 24891645 )
2014
25
Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study. ( 24799029 )
2014
26
Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in SjAPgren syndrome patients with or without punctal occlusions. ( 24977983 )
2014
27
The Role of Chlamydia Pneumoniae in the Etiology Keratoconjunctivitis Sicca (KCS). ( 25395268 )
2014
28
Bilateral parotid duct transposition for keratoconjunctivitis sicca in a Connemara stallion. ( 23067239 )
2013
29
Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. ( 23884332 )
2013
30
A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs. ( 22853450 )
2013
31
Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. ( 23813419 )
2013
32
Corneal sequestrum in a dog with chronic unilateral keratoconjunctivitis sicca. ( 24299547 )
2013
33
Infrared ocular thermography in dogs with and without keratoconjunctivitis sicca. ( 23905697 )
2013
34
Punctal plugs versus artificial tears for treating primary SjAPgren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function. ( 23649850 )
2013
35
Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits. ( 23514268 )
2013
36
Dacryocystorhinostomy precipitating keratoconjunctivitis sicca in aplasia of lacrimal and major salivary glands (ALSG). ( 21659912 )
2012
37
Proteomic analysis of secretion from human transplanted submandibular gland replacing lacrimal gland with severe keratoconjunctivitis sicca. ( 22306964 )
2012
38
Canine neurogenic Keratoconjunctivitis sicca: 11 cases (2006-2010). ( 22051024 )
2012
39
Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjogren's syndrome. ( 21558290 )
2012
40
Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs. ( 25653763 )
2012
41
An experimental study of the management of severe keratoconjunctivitis sicca with autologous reduced-sized submandibular gland transplantation. ( 22051179 )
2012
42
Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis in Cavalier King Charles spaniel dogs. Part II: candidate gene study. ( 22339941 )
2012
43
Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. ( 22041848 )
2012
44
Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis in 25 Cavalier King Charles spaniel dogs. Part I: clinical signs, histopathology, and inheritance. ( 22212237 )
2012
45
Effects of topical human amniotic fluid and human serum in a mouse model of keratoconjunctivitis sicca. ( 22290385 )
2012
46
Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. ( 21958171 )
2011
47
Treatment of severe keratoconjunctivitis sicca by parotid duct transposition after tympanic neurectomy in rabbits. ( 21828155 )
2011
48
Disruption of TGF-I^ signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. ( 22194977 )
2011
49
Establishment of a rabbit model for keratoconjunctivitis sicca. ( 21659853 )
2011
50
Keratoconjunctivitis sicca of human T cell lymphotropic virus type 1 (HTLV-1) infected individuals is associated with high levels of HTLV-1 proviral load. ( 21868282 )
2011

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

Pathways related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CD79A ERBB2 ERBB3 IL1A IL1B IL4
2
Show member pathways
13.7 ERBB2 ERBB3 IL1A IL1B IL4 IL6
3
Show member pathways
13.56 ERBB2 ERBB3 IL1A IL1B IL4 IL6
4
Show member pathways
13.4 ERBB2 ERBB3 IL1A IL1B IL4 IL6
5
Show member pathways
13.37 ERBB2 ERBB3 IL1A IL1B IL4 IL6
6
Show member pathways
13.33 ERBB2 IL1A IL1B IL4 IL6 NGF
7
Show member pathways
13.19 CD79A ERBB2 ERBB3 IL1A IL1B IL4
8
Show member pathways
13.03 IL1A IL1B IL6 TLR4 TLR9 TNF
9
Show member pathways
12.96 HSPG2 IL1B IL6 TLR4 TLR9 TNF
10
Show member pathways
12.87 IL1A IL1B IL4 IL6 TNF
11
Show member pathways
12.83 IL1A IL1B IL4 IL6 TLR4 TLR9
12
Show member pathways
12.72 IL1A IL1B IL6 NGF TLR4 TLR9
13
Show member pathways
12.68 IL1A IL1B NGF TLR4 TLR9 TNF
14
Show member pathways
12.64 IL1A IL1B IL4 IL6 TLR4 TNF
15 12.6 CD79A IL1B IL4 TLR9 TNF
16
Show member pathways
12.49 IL1A IL1B IL4 IL6 TNF
17
Show member pathways
12.45 ERBB2 ERBB3 IL1A IL1B
18
Show member pathways
12.4 ALB IL1B IL4 IL6 TNF
19 12.37 ERBB2 ERBB3 HSPG2 TLR4 TNF
20
Show member pathways
12.36 IL1B IL4 IL6 TNF
21
Show member pathways
12.34 IL1A IL6 TLR4 TLR9 TNF
22
Show member pathways
12.33 IL1A IL1B IL6 TLR4 TNF
23
Show member pathways
12.32 IL1A IL1B IL4 TLR4 TNF
24 12.23 IL6 TLR4 TLR9 TNF
25 12.23 IL1A IL1B IL6 NGF TNF
26
Show member pathways
12.21 IL1A IL1B IL4 IL6 TNF
27 12.21 IL1A IL1B IL6 TLR4 TLR9 TNF
28
Show member pathways
12.1 IL1B IL4 IL6 TLR4 TLR9 TNF
29 12.06 CD79A IL4 IL6 TNF
30 12.05 IL1A IL1B IL4 IL6 TNF
31
Show member pathways
12.01 IL1B IL6 TLR4 TLR9 TNF
32 11.98 IL1A IL1B IL6 TNF
33
Show member pathways
11.97 IL1B IL4 IL6 TLR4 TLR9
34 11.96 IL1B IL6 TLR4 TNF
35
Show member pathways
11.94 ERBB2 ERBB3 IL1A IL1B TLR4 TLR9
36 11.91 ERBB2 IL6 TLR4
37 11.91 IL1A IL1B IL6 TLR4
38 11.89 CD79A HSPG2 IL6
39 11.89 IL1B TLR4 TNF
40 11.89 IL1A IL1B IL4 IL6 TNF
41 11.85 IL1A IL1B IL6 TLR4 TNF
42 11.84 IL1B IL6 TLR9 TNF
43 11.81 IL1B IL4 TNF
44 11.74 IL1B IL4 IL6 TNF
45
Show member pathways
11.74 IL1A IL1B IL6 TNF
46 11.74 IL1A IL1B IL6 TLR4 TNF
47 11.71 IL1A IL1B IL4 IL6 TLR4 TNF
48 11.68 IL4 IL6 TLR4 TLR9 TNF
49 11.66 IL1B IL6 TLR4 TNF
50 11.63 IL1A TLR4 TNF

GO Terms for Keratoconjunctivitis Sicca

Cellular components related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ALB ERBB3 HSPG2 IL1A IL1B IL4
2 external side of plasma membrane GO:0009897 9.55 CD79A IL4 IL6 TLR4 TNF
3 extracellular region GO:0005576 9.4 ALB ERBB3 HSPG2 IL1A IL1B IL4

Biological processes related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show all 50)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.98 ALB HSPG2 IL6 LTF
2 defense response to bacterium GO:0042742 9.97 LTF TLR4 TLR9 TNF
3 MAPK cascade GO:0000165 9.97 ERBB2 ERBB3 IL1B NRTN TNF
4 positive regulation of protein phosphorylation GO:0001934 9.93 ERBB2 IL1B IL4 TNF
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 IL1B LTF TLR4 TLR9 TNF
6 wound healing GO:0042060 9.88 ERBB2 ERBB3 IL6
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 ERBB2 ERBB3 NGF NRTN
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.87 IL1B IL4 IL6 TNF
9 positive regulation of T cell proliferation GO:0042102 9.84 IL1B IL4 IL6
10 humoral immune response GO:0006959 9.83 IL6 LTF TNF
11 positive regulation of interferon-gamma production GO:0032729 9.81 IL1B TLR4 TNF
12 positive regulation of JNK cascade GO:0046330 9.81 IL1B TLR4 TLR9 TNF
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.79 IL1A IL1B TNF
14 defense response to Gram-negative bacterium GO:0050829 9.78 IL6 LTF TLR4 TLR9
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 IL1B TLR4 TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 IL1B IL6 TLR4 TNF
17 negative regulation of interleukin-6 production GO:0032715 9.72 TLR4 TLR9 TNF
18 negative regulation of ERBB signaling pathway GO:1901185 9.71 ERBB2 ERBB3
19 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 IL1B TNF
20 positive regulation of interleukin-10 production GO:0032733 9.71 IL4 TLR4 TLR9
21 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.71 ERBB3 IL1A IL1B IL4
22 I-kappaB phosphorylation GO:0007252 9.7 TLR4 TLR9
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL1B TNF
24 regulation of cytokine secretion GO:0050707 9.7 TLR4 TLR9
25 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.69 IL1A IL1B
26 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.69 IL1B TLR9
27 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
28 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 TLR4 TNF
29 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.68 IL1A IL1B
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL4 TLR4
31 ectopic germ cell programmed cell death GO:0035234 9.67 IL1A IL1B
32 positive regulation of interleukin-8 production GO:0032757 9.67 IL1B TLR4 TLR9 TNF
33 regulation of establishment of endothelial barrier GO:1903140 9.66 IL1B TNF
34 positive regulation of interferon-beta biosynthetic process GO:0045359 9.65 TLR4 TLR9
35 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.65 IL6 TNF
36 positive regulation of fever generation GO:0031622 9.64 IL1B TNF
37 positive regulation of chemokine biosynthetic process GO:0045080 9.63 IL1B IL4 TNF
38 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 IL1B IL6 LTF TLR4 TLR9 TNF
39 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
40 positive regulation of mononuclear cell migration GO:0071677 9.62 IL4 TNF
41 positive regulation of NF-kappaB import into nucleus GO:0042346 9.62 IL1B TLR4 TLR9 TNF
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 IL1B TNF
43 positive regulation of gene expression GO:0010628 9.61 ERBB2 ERBB3 IL1A IL1B IL6 NGF
44 fever generation GO:0001660 9.6 IL1A IL1B
45 positive regulation of chemokine production GO:0032722 9.56 IL6 TLR4 TLR9 TNF
46 positive regulation of interleukin-6 production GO:0032755 9.1 IL1A IL1B IL6 TLR4 TLR9 TNF
47 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.17 IL1A IL1B IL4 IL6 TLR4 TLR9
48 negative regulation of apoptotic process GO:0043066 10.09 ALB IL4 IL6 LTF NGF
49 immune response GO:0006955 10.03 IL1A IL1B IL4 IL6 TLR4 TNF
50 inflammatory response GO:0006954 10 IL1A IL1B IL6 TLR4 TLR9 TNF

Molecular functions related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL4 IL6 NGF NRTN
2 transmembrane signaling receptor activity GO:0004888 9.55 CD79A ERBB2 ERBB3 TLR4 TLR9
3 cytokine activity GO:0005125 9.35 IL1A IL1B IL4 IL6 TNF
4 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B TLR9

Sources for Keratoconjunctivitis Sicca

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....